Placed machines, reagent tenders and 24-month contracts: how a Vietnamese hospital lab chief buys an analyser
Summary
- In a public hospital lab the analyser normally arrives placed by the reagent supplier, with the machine's cost inside the price of the test; the 2023 bidding law, in force since 1 January 2024, names this route and says only the right to use passes to the hospital. 1 2
- Packages are big and short: Việt Đức Hospital tendered 105.833 billion VND of reagents with equipment for 24 months, 78.991 billion of it for one immunoassay lot. 3 4
- Specification fights are about capacity and backup: a 2026 Ho Chi Minh City tender asked for analysers of at least 1,600 tests per hour each, and a bidder said the figure matched one brand. 5
- Reagent money comes out of hospital service revenue (273.113 billion VND at Bạch Mai Hospital for 2025–2027), so the lab head must justify revenue, cost and turnaround time to a senior panel. 6 7
- Reagents are not on the national centralised list: Circular 01/2026/TT-BYT, effective 1 March 2026, itemises only lenses and stents, and reagents tie to analyser platforms. 8 9
- Labs upgrade rather than switch: references from peer labs, technician resistance and a preference for one or two integrated brands protect the incumbent, unless a cheaper reagent comes with no lock-in. 10 11 12 13
Transcript
01How an analyser really arrives
Let's start with the basics. When your lab needs a new analyser, do you buy it?
Mostly no, and that surprises newcomers. In a public hospital lab the analyser usually arrives placed by the reagent supplier, so what we really sign is a reagent contract. The cost of the machine is carried inside the price of every test rather than shown as a line of its own. 1 People say máy đặt, máy mượn, the placed machine or the borrowed machine. The law now names the model plainly: the supplier who wins the reagent package may bring the equipment, but only the right to use it passes to us, never ownership. So when I say 'my analyser', I mean the analyser I am allowed to use. 2
How big are these deals, and how long do they run?
Big, and shorter than people think. Take a tender listing from this January: Việt Đức Hospital packaged reagents and consumables that come with equipment and supporting tools at 105.833 billion dong, for 24 months, on a fixed unit price. One lot alone, the chemiluminescent immunoassay, was 78.991 billion, against 8.901 billion for coagulation and 7.546 billion for blood cell counting. 3 That is why immunoassay is where every supplier fights. Hepatitis testing keeps the reagent volume high and the margin with it. 4
A provincial hospital like mine is smaller, but the rhythm is the same. This July a provincial general hospital in Quảng Trị put out a request for price quotes on reagents and test supplies with machines supplied alongside, for 24 months covering 2026 to 2028. The notice says the quotes help the hospital build its price and organise the selection of the contractor. 14
02The choices the law gives a lab
You said the law names the model. What can a lab chief actually choose between, on paper?
Four routes, the way I keep them in my head. First, reagents with the equipment on loan, right of use only. Second, a pay-per-service deal: the contractor supplies reagents, equipment, spare parts and the related services, we pay per number of technical services as written in the bid documents, only the right to use passes to us, they do not give us operators, and it cannot run longer than 5 years. Third, a buy-out, where machine, reagents and supplies all become the hospital's once the contract takes effect. Fourth, reagents only, to run a machine we already own. 2 Which one we use depends on whether the board will put up capital in the year. If not, we are in placement. 1
Do hospitals mix them, own one machine and borrow another?
Some large hospitals buy the main analyser outright to escape the mark-up on reagents, then rent the backup unit, because it sits idle most of the time. 15 The mixing is where the paperwork gets tangled. A tendering newspaper put a case to its roundtable this August: a hospital package using the reagents-only route for machines the hospital already runs, with documents demanding compatibility with those machines, but also demanding that the winner lend a machine when needed. The author's numbers were yearly demand of 1,000,000 samples against existing machines that handle 500,000, and a suggested split of 500,000 samples under each route. 16
The author then asks whether health insurance would validly pay for tests run on the borrowed machine, and the page gives no answer. I can't give you one either. Ask your hospital's finance office and the insurance office, and get it in writing before you plan around it. 16
03Writing the specification
Who writes the technical specification, and who has to agree to it?
My senior technologists and I draft the technical part. Then it goes through the usual route: shortlisting by the equipment or materials office, input from the clinicians who send us samples, trials of the candidate systems, and finally a senior panel. The clinicians' input is not a formality, because they live with our turnaround time and are the first to complain when results are late. In front of the senior panel I have to justify what the machine will earn, what it will cost, and how fast results come out. 7
Where do specifications go wrong? Is there a recent case you remember?
Capacity, every time. Read the 2026 reagent tender of Trung Mỹ Tây Hospital in Ho Chi Minh City. The documents asked for 2 biochemistry analysers of at least 1,600 tests per hour each, for an expected 1,091,542 tests a year. A bidder did the sum: over 260 to 300 working days that is about 3,600 to 4,200 tests a day, so 2 machines at 3,200 tests per hour combined looked far too big, and it said the specifications matched one brand's model. 5
The hospital held its ground on 1,600 tests per hour per machine, citing the peak hours, backup when one machine is down for maintenance or failure, and growth. It dropped several detailed specifications, rewrote the emergency requirement as simply the ability to run emergency samples, and extended the closing date to 29 December 2025. In my view the hospital is right about backup; when the only analyser stops, nobody cares whose tender it was. But the bidder's point about brand-shaped wording also lands. 5
04Budgets, insurance and the national list
Where does the money for reagents and placed machines come from?
From what the hospital earns. The big central hospitals fund these packages from their medical service revenue. Bạch Mai Hospital's estimate for 2025 to 2027 is 273.113 billion dong in 7 packages by open bidding, the largest, at 100.107 billion, covering biochemistry and haematology with blood transfusion at its second campus. 6 Bệnh viện E's second round is 733.94 billion over 4 packages, with the lab reagents and consumables for machines together in one package of 281.942 billion, 24 months, again by open online bidding. 17 So a lab's reagent budget is argued against revenue. If my department's revenue does not carry its cost, I hear about it. 7
And what does health insurance have to do with it?
A great deal. The amended health insurance law took effect on 1 July 2025, and the fund pays for technical services, drugs, equipment, consumables and chemicals used in medical examination and treatment, as long as they fall within the fund's payment scope. 18 The sums are large: for 2024 the fund received requests for payment of 142,985 billion dong across 186.2 million visits. 19 But volume is not a gift. Hospitals tighten controls on unnecessary tests, and patients who pay themselves, the lower-income ones above all, often skip testing. 20
Reagents are bought hospital by hospital. Is that about to change?
Not for reagents yet, as far as I can see. The Ministry's circular on the national centralised procurement list took effect on 1 March 2026, with centralised purchasing due from 1 January 2027, and the two groups in it are intraocular lenses and coronary stents. The published summary I read itemises no reagents or analysers, so for now the reagent tender is still ours to run. 8 Whether reagents ever join, I can't tell you. It would be hard, because every analyser needs reagents made for its platform and labs run different equipment. 9
05Choosing a supplier and living with it
When two suppliers offer a placed analyser, how do you decide?
First, the all-in cost of one test over the length of the contract. In a placement the machine hides inside that number, so I compare the number, not the machine. 1 Second, whether one brand can cover my menu, so I am not running many platforms and many interfaces. Labs are consolidating on one or two major brands with a single interface, though the biggest reference hospitals keep some variety. 21 Third, people. Automation pays for itself mainly in saved staff time, and a lab short of hands will lean toward the integrated system. 22
Do you deal with the maker or with a distributor?
Both exist. A foreign supplier sells through a licensed local distributor that holds the import licence and issues the invoice, while the leading brands do the selling and the technical service with their own teams. When the invoice and the engineer come from two different companies, I end up chasing both. 23 The smaller brands leave service to the distributor, and that is where I get nervous. Labs generally complain about distributors' responsiveness and technical knowledge and would rather deal with the maker, and a brand that changes distributor can lose accounts. 24
06Replacing and upgrading
When do you replace an analyser, and does new capital ever arrive?
Rarely on my own timetable. Routine chemistry and haematology run on long equipment cycles, and suppliers grow there by taking share from each other, not because everybody replaces at once. 25 For me the real moment is the end of the contract, because a placed machine leaves with the contract, so the replacement is decided when the next reagent package is planned. The Quảng Trị notice of July 2026, asking for quotes for 24 months covering 2026 to 2028, is that rhythm in action. 14 New capital arrives for some. Large urban hospitals replace old equipment under government upgrade programmes, small hospitals still buy cheaper equipment outright, and many district hospitals depend on aid-funded equipment. A provincial lab like mine sits in between, and I would not count on capital arriving the month an instrument fails. 26
Would you rather switch brands or upgrade, and what could move you?
Upgrade, nearly always. Labs prefer to upgrade what they have over switching brands, and we want a supplier who behaves like a partner, not a vendor. 12 Switching also means my technologists face retraining, and some quietly fear for their jobs; nobody on the bench wants the extra work, and suppliers know it, so they sell to the director on cost and profit. I put the technologists into any trial so the resistance is heard early. 11
What can move us is a cheaper reagent. Budget-pressed hospitals prefer placements without lock-in contracts so they can switch when one appears, and small brands from Korea, China and Germany are testing that door. 13 27 Even then I want to phone a hospital already running the system, because nobody wants to be the first, and a supplier with a flagship reference is easier to approve. 10 28
07Advice to a newcomer, and what worries me
A Japanese or Korean maker wants to place analysers in Vietnamese public hospital labs. What would you tell them?
Come with an all-in price per test and a clear contract period, and expect the tender to be for 24 months, as in the Việt Đức Hospital package. 3 Bring a reference hospital I can phone. 10 Make sure your distributor holds the licence and invoices properly, and that your own people can pick up a service call. 23 Be ready for my board to ask what the machine earns, what it costs and how fast results come out. 7 And do not copy your brochure into the specification; the Trung Mỹ Tây Hospital case shows a rival bidder will check. 5
One more thing on paperwork. What do you check when a supplier brings a new reagent?
I ask for the registration and import papers. If I read Decree 04/2025 right, the old import licences for diagnostic products issued from 1 January 2018 to 31 December 2021 and the older circulation registration numbers were allowed until 30 June 2025, and that date has passed. So I expect a current registration, and I would not take a supplier's word for it. I ask for the registration number and the import papers and keep copies in the tender file. 29
Last question. What worries you, or what would change your mind about this model?
Three things. One, if the national centralised list ever reaches reagents, I could lose the choice of platform; the circular makes centralised purchasing due from 1 January 2027, though for now it names only lenses and stents. 8 Two, the open question on insurance payment for tests on mixed owned and borrowed machines, which I cannot resolve for you. 16 Three, price pressure from cheap suppliers squeezing service until the best brands cut corners. 27 If those three stay quiet, placement stays the sensible way to equip a public lab. 1
Sources and basis
- 1Analysers usually enter a public hospital lab placed by the reagent supplier, with the machine's cost recovered through reagent volume rather than a separate purchase, so labs compare suppliers on the all-in cost of a testKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 2Law on Bidding 22/2023/QH15, in force from 1 Jan 2024, Article 55 on buying reagents, lab supplies and medical equipment: the winner of a reagent and lab-supply package may also supply the equipment, transferring only the right to use it, not ownership; or the contractor supplies reagents, equipment, spare parts and related operating services paid per number of technical services (dịch vụ kỹ thuật) stated in the bid documents, without operating staff and again transferring only the right to use, for no more than 5 years (không quá 05 năm); or a buy-out where ownership of equipment, reagents and supplies passes to the hospital from when the contract takes effect; or reagents and supplies only, to run equipment the hospital already hasPublic source · Law on Bidding 22/2023/QH15, Article 55(1), official consolidated text 74/VBHN-VPQH (National Assembly Office, 2026), in force since 1 Jan 2024 · link
- 3Báo Đấu thầu, 21 Jan 2026: Việt Đức Hospital package 12, reagents and consumables supplied with equipment and supporting tools, priced at 105.833 billion VND, 24 months, fixed unit price, open bidding, funded from medical service revenue; lot 1 (chemiluminescent microparticle immunoassay) 78.991 billion VND, lot 2 (automated coagulation) 8.901 billion, lot 3 (automated peripheral blood cell analysis) 7.546 billionPublic source · Báo Đấu thầu, 21 Jan 2026 · link
- 4Hepatitis testing dominates immunoassay reagent use, and immunoassay margins are highKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 5Báo Đấu thầu, 29 Jan 2026, on the 2026 tender of Trung Mỹ Tây Hospital (Ho Chi Minh City) for lab reagents with placed machines: the documents required 2 biochemistry analysers of at least 1,600 tests per hour each, for expected annual volume of 1,091,542 tests; a bidder calculated about 3,600 to 4,200 tests a day over 260 to 300 working days, said 2 machines at 3,200 tests per hour combined far exceeded need and said the specifications matched one brand's model; the hospital kept 1,600 tests per hour per machine, citing peak-hour demand, backup during maintenance or failure and future expansion, dropped several detailed specifications, reworded the emergency (STAT) requirement to the ability to run emergency samples, and extended the closing date to 29 Dec 2025 (revision decision of 15 Dec 2025)Public source · Báo Đấu thầu, 29 Jan 2026 · link
- 6Báo Đấu thầu, 4 Dec 2025: Bạch Mai Hospital's procurement of lab supplies and reagents for 2025–2027 has a total estimate of 273.113 billion VND, funded from the hospital's medical service revenue, in 7 packages by open bidding; the largest, biochemistry and haematology–blood transfusion at campus 2, is 100.107 billion VNDPublic source · Báo Đấu thầu, 4 Dec 2025 · link
- 7Public hospital purchases run through a specification, shortlisting by the equipment or materials office, clinician input, trials and a senior panel; the lab head must justify the revenue, cost and turnaround timeKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 8Ministry of Health Circular 01/2026/TT-BYT (issued 9 Jan 2026) on the national centralised procurement catalogue for medical equipment and lab supplies takes effect on 1 Mar 2026, with centralised procurement from 1 Jan 2027; as reported by the Government's news agency, the two item groups are intraocular lenses and coronary stents, and no reagents or analysers are itemisedPublic source · Circular 01/2026/TT-BYT, as reported by Báo Chính phủ (Government news agency), Jan 2026 · link
- 9Reagents are hard to tender centrally because labs run different equipment and each analyser needs reagents made for its platformKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 10Labs avoid being the first user of a new analyser; references from peer labs and a trial period weigh heavily in the choiceKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 11Lab technicians may resist new automated systems for fear of retraining or job loss, and middle managers dislike the workload of switching brands, so suppliers sell to senior management on cost and profitKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 12Labs prefer to upgrade what they have over switching brands, and want a supplier that acts as a partner rather than a vendorKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 13Budget-pressed hospitals prefer placements without lock-in contracts so they can switch when a cheaper reagent appearsKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 14Quảng Trị Provincial General Hospital notice, 27 Jul 2026: seeking price quotes for lab chemicals and test supplies with machines supplied alongside, for 24 months covering 2026–2028, citing point d, clause 2, Article 18 of Decree 214/2025/NĐ-CP, as a reference for building the price and as the basis for organising contractor selectionPublic source · Quảng Trị Provincial General Hospital, 27 Jul 2026 · link
- 15Some large hospitals buy the main analyser outright to avoid reagent mark-ups but rent the under-used backup unitKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 16Báo Đấu thầu roundtable, 26 Aug 2026: a hospital package for lab reagents under point đ, clause 1, Article 55 required the supplies to be compatible with the hospital's existing equipment, yet also required the winner to lend equipment when the hospital needed it; the author's example is annual demand of 1,000,000 samples against existing equipment capacity of 500,000 samples a year, with a suggested split of 500,000 samples under point đ and 500,000 under point a; it asks whether health insurance payment for tests on the borrowed machine would be valid and gives no expert answerPublic source · Báo Đấu thầu, 26 Aug 2026 · link
- 17Báo Đấu thầu, 28 Aug 2025: Bệnh viện E's second-round procurement of supplies and reagents for 2025–2027 has a total estimate of 733.94 billion VND in 4 packages by open online bidding, 24 months, funded from medical service revenue; lab reagents and consumables for machines sit together in one package, VT9, at 281.942 billion VNDPublic source · Báo Đấu thầu, 28 Aug 2025 · link
- 18LSVN, 17 May 2025: the amended health insurance law, Law 51/2024/QH15, takes effect on 1 Jul 2025; the insurance fund pays for medical technical services, drugs, equipment, blood, medical gases, consumables, tools and chemicals used in medical examination and treatment, as long as they fall within the fund's payment scopePublic source · LSVN, 17 May 2025 · link
- 19LSVN, 13 Jan 2025: for 2024 the health insurance fund received requests for payment of 142,985 billion VND across 186.2 million inpatient and outpatient visits; this is the amount requested, and the article gives no separate figure for the amount paidPublic source · LSVN, 13 Jan 2025 · link
- 20Hospitals apply cost controls to curb unnecessary tests and purchases, and lower-income patients who pay for tests themselves often skip themKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 21Labs are consolidating on one or two major brands with integrated systems and a single interface, while the largest reference hospitals keep some diversityKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 22Automation is justified mainly by manpower savings; labs short of staff look for integrated automated systemsKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 23Foreign suppliers sell through licensed local distributors that hold the import licence and issue the invoice, while the leading brands do the selling and technical service with their own teamsKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 24Labs often dislike buying through distributors, citing poor responsiveness and technical knowledge, and prefer to deal with the supplier directly; a change of distributor can cost a brand its shareKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 25Routine chemistry and haematology are replacement markets on long equipment cycles; supplier growth there comes from taking shareKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 26Large urban hospitals replace old equipment under government upgrade programmes; small hospitals still buy cheaper equipment outright, and many district hospitals depend on aid-funded equipmentKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 27Low-price reagent suppliers, many of them small brands from Korea, China and Germany, undercut the major brands as hospital budgets shrinkKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 28A supplier's first big customer becomes a reference site that unlocks other labs; suppliers place a system to win the account because the reference is worth more than the marginKIRA field interviews · KIRA field interviews, Vietnam and neighbouring markets
- 29Decree 04/2025/NĐ-CP (issued 1 Jan 2025), amending Decree 98/2021/NĐ-CP as amended by Decree 07/2023/NĐ-CP: import licences for in-vitro diagnostic products issued from 1 Jan 2018 to 31 Dec 2021 stay usable until 30 Jun 2025 (previously 31 Dec 2024) with no limit on import quantity, and circulation registration numbers for such products registered from 1 Jan 2014 to 31 Dec 2019 stay valid until 30 Jun 2025Public source · Decree 04/2025/NĐ-CP, 1 Jan 2025 (text via caselaw.vn) · link